3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Cyclophosphamide
118
Peripheral Blood Stem Cell Transplantation
67
Filgrastim
60
Etoposide
60
Rituximab
54
fludarabine phosphate
50
Vincristine
46
Radiotherapy
46
Methotrexate
46
Cytarabine
44
Doxorubicin
40
Cyclosporine
35
Mycophenolic Acid
33
Busulfan
33
Prednisone
32
Whole-Body Irradiation
31
Tacrolimus
28
Antilymphocyte Serum
28
Melphalan
27
Dexamethasone
26
Methylprednisolone
22
Leucovorin
19
Carmustine
18
Granulocyte Colony-Stimulating Factor
17
Calcium Dobesilate
16
Ifosfamide
15
Psychiatric Rehabilitation
13
Cord Blood Stem Cell Transplantation
13
sargramostim
12
merphos
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Burkitt Lymphoma
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts